RT @jcsam25: @RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data sh
Tweet Content
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Show on Archive Page
On
Display in Search Results
On